Overview

N-acetyl Cysteine for the Prevention of Oral Mucositis After Autologous Hematopoietic Cell Transplantation.

Status:
Not yet recruiting

Trial end date:
2023-03-31

Target enrollment:

Participant gender:

Summary

Oral mucositis (OM) is a major source of morbidity in patients undergoing hematopoietic cell transplantation (HCT). N-acetyl cysteine (NAC) is an antioxidant, widely used as mucolytic agent or antidote of acetaminophen overdose hepatotoxicity. we intend to explore the safety and efficacy of NAC in the prevention of OM after high-dose chemotherapy and autologous HCT in a phase III, randomized, open label and multi-center study.

Phase:

Phase 3

Details

Lead Sponsor:

moshe yeshurun

Treatments:

Acetylcysteine
N-monoacetylcystine